香港股市 已收市

FibroGen, Inc. (FGEN)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
2.4950-0.0850 (-3.29%)
市場開市。 截至 11:42AM EDT。
全螢幕
交易股價資料並非來自所有市場
前收市價2.5800
開市2.5800
買盤2.4600 x 100
賣出價2.5200 x 200
今日波幅2.4200 - 2.5900
52 週波幅0.3330 - 20.9000
成交量525,643
平均成交量2,627,211
市值246.434M
Beta 值 (5 年,每月)0.66
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-2.9200
業績公佈日2024年5月06日 - 2024年5月10日
遠期股息及收益率無 (無)
除息日
1 年預測目標價1.25
  • Zacks

    Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

    Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.

  • InvestorPlace

    3 Nightmare Nasdaq Stocks Not Worth Holding Another Day

    Stocks are at the mercy of many factors, and often, prices are just a poor earnings report or a negative headline away from a significant drop. There are times when nobody has any way of preparing. In many instances, however, early signs of trouble creep in. Sensible investors can identify potential issues from declining financial reports, brewing service problems, poorly managed spending, or questionable business decisions. Unfortunately, these three companies all show these signs, which may me

  • Zacks

    Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals

    Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.